臨床整形外科54巻7号

2019年07月発行

誌上シンポジウム 骨軟部腫瘍の薬物治療アップデート

骨巨細胞腫に対するデノスマブ治療

著者： 浦川浩¹² 新井英介¹ 生田国大¹ 大田剛広¹ 酒井智久¹ 西田佳弘¹³

所属機関： ¹名古屋大学医学部整形外科 ²名古屋大学医学部附属病院化学療法部 ³名古屋大学医学部附属病院リハビリテーション科

ページ範囲：P.665 - P.670

　骨巨細胞腫は若年成人の長管骨の骨幹端から骨端にかけて好発する骨原発腫瘍で，組織学的に良性と悪性の中間に位置するintermediateに分類される．局所の骨破壊を特徴とし，関節破壊を来し，しばしば治療に難渋する．2014年から骨巨細胞腫に対して抗RANKL抗体であるデノスマブが保険適用となり，骨巨細胞腫の病勢コントロールや手術の低侵襲化など広く恩恵を受けられるようになった．本稿ではこれまでの骨巨細胞腫に対するデノスマブ治療のエビデンスを概説し，デノスマブを用いた骨巨細胞腫の治療戦略について述べる．

参考文献

1) Campanacci M, Baldini N, Boriani S, et al. Giant-cell tumor of bone. J Bone Joint Surg Am 1987;69(1):106-14.

2) Goldenberg RR, Campbell CJ, Bonfiglio M. Giant-cell tumor of bone. An analysis of two hundred and eighteen cases. J Bone Joint Surg Am 1970;52(4):619-64.

3) Athanasou NA, Bansal M, Forsyth R, et al. Giant cell tumour of bone. In:Fletcher CDM, Bridge JA, Hogendoorn PCW, et al. editors. WHO Classification of Tumours of Soft Tissue and Bone. 4 ed. Lyon:IARC Press;2013. p.321-4.

4) Morgan T, Atkins GJ, Trivett MK, et al. Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol 2005;167(1):117-28.

5) Yamagishi T, Kawashima H, Ogose A, et al. Receptor-activator of nuclear kappaB ligand expression as a new therapeutic target in primary bone tumors. PLoS One 2016;11(5):e0154680. doi:10.1371/journal.pone.0154680.

6) Branstetter DG, Nelson SD, Manivel JC, et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res 2012;18(16):4415-24.

7) Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone:an open-label, phase 2 study. Lancet Oncol 2010;11(3):275-80.

8) Mak IW, Evaniew N, Popovic S, et al. A translational study of the neoplastic cells of giant cell tumor of bone following neoadjuvant denosumab. J Bone Joint Surg Am 2014;96(15):e127. doi:10.2106/JBJS.M.01332.

9) Chawla S, Henshaw R, Seeger L, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone:interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 2013;14(9):901-8.

10) Palmerini E, Chawla NS, Ferrari S, et al. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB):For how long? Eur J Cancer 2017;76:118-24.

11) Puri A, Gulia A, Hegde P, et al. Neoadjuvant denosumab:its role and results in operable cases of giant cell tumour of bone. Bone Joint J 2019;101-B(2):170-7.

12) Errani C, Tsukamoto S, Leone G, et al. Denosumab may increase the risk of local recurrence in patients with giant-cell tumor of bone treated with curettage. J Bone Joint Surg Am 2018;100(6):496-504.

13) Urakawa H, Mizusawa J, Tanaka K, et al. A randomized phase III trial of denosumab before curettage for giant cell tumor of bone:Japan Clinical Oncology Group Study JCOG1610. Jpn J Clin Oncol 2019;49(4):379-82.

14) Urakawa H, Yonemoto T, Matsumoto S, et al. Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan:from a questionnaire for JCOG 1610 study. World J Surg Oncol 2018;16(1):160. doi:10.1186/s12957-018-1459-6.

15) Luo Y, Tang F, Wang Y, et al. Safety and efficacy of denosumab in the treatment of pulmonary metastatic giant cell tumor of bone. Cancer Manag Res 2018;10:1901-6.

16) Yamagishi T, Kawashima H, Ogose A, et al. Disappearance of giant cells and presence of newly formed bone in the pulmonary metastasis of a sacral giant-cell tumor following denosumab treatment:a case report. Oncol Lett 2016;11(1):243-6.

17) Demirsoy U, Karadogan M, Selek Ö, et al. Golden bullet-denosumab:early rapid response of metastatic giant cell tumor of the bone. J Pediatr Hematol Oncol 2014;36(2):156-8.

18) Tsukamoto S, Mavrogenis AF, Leone G, et al. Denosumab does not decrease the risk of lung metastases from bone giant cell tumour. Int Orthop 2019;43(2):483-9.

19) Medellin MR, Fujiwara T, Tillman RM, et al. Prognostic factors for local recurrence in extremity-located giant cell tumours of bone with pathological fracture. Bone Joint J 2018;100-B(12):1626-32.

20) Traub F, Singh J, Dickson BC, et al. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone. Eur J Cancer 2016;59:1-12.